CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Satellos Bioscience Inc. (MSLE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Satellos Bioscience Inc. (MSLE)

Pharmaceutical Preparations · market cap $135M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-03-31 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Satellos Bioscience (MSLE) is a ~$101M market-cap, 14-employee company whose only pipeline asset in our database is SAT-3247, in Phase 2 for Duchenne Muscular Dystrophy. The setup is a single-asset story. Our calendar shows an estimated Phase 2 SAT-3247 event on 2027-03-31 (importance 7/10), and the balance sheet figure we hold looks thin against the burn.
The catalyst path
  • 2027-03-31 (est.)Phase 2 · SAT-3247imp 7/10
Pipeline
AssetPhaseIndication
SAT-3247Phase 2Duchenne Muscular Dystrophy
Price & technical context
3-month
-33.3%
6-month
-5.4%
12-month
+10.5%
52-wk range
$5.59–$13.01
vs 50-day MA
-14.7%
vs 200-day MA
-20.5%
Realized vol
82.4%
Max drawdown
-57.0%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for MSLE (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.